Please assess the completion status of the following clinical trial:

Trial Title: An International Trial to Evaluate the Efficacy and Safety of SABER®-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subacromial impingement syndrome~* MRI with intact rotator cuff~* Patients suitable for general anaesthesia~Exclusion Criteria:~* Known major joint trauma, infection, avascular necrosis, chronic dislocation, inflammatory or degenerative glenohumeral arthropathy, glenohumeral arthritis, frozen shoulder or previous surgery of the affected shoulder~* Abnormal ECG~* Prolonged QT syndrome~* Current or regular use of analgesic medication for other indication(s)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SABER-Bupivacaine Treatment 1a (Type: EXPERIMENTAL): double-blind
- Placebo SABER-Bupivacaine Treatment 1b (Type: PLACEBO_COMPARATOR): double-blind
- Bupivacaine HCl Treatment 1c (Type: ACTIVE_COMPARATOR): double-blind
- SABER-Bupivacaine Treatment 2a (Type: EXPERIMENTAL): double-blind
- Placebo SABER-Bupivacaine Treatment 2b (Type: PLACEBO_COMPARATOR): double-blind
- Bupivacaine HCl Treatment 2c (Type: ACTIVE_COMPARATOR): double-blind

Based on this trial design, predict the completion outcome and termination type (if applicable).